US22053A1079
© BusinessWire
10.12.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Participate at Investor Events in December 2025
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025:
Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Office...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025.
Dirk Thye, M.D., Quince’s Chief...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
10.11.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for the company’s ongoing pivotal P...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
02.09.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the H.C. Wainwright 27th Annual Global Investment Conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical tr...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysic...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy gro...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock (or...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of i...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative diseas...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2025.
Dirk Thye, M.D., Quince’s Chief Execu...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.04.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Present at Citizens Life Sciences Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on W...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the fiscal year ended December 31, 2024.
Dirk Thye, M.D., Quince’s Chief Exec...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that it will host an investor webinar today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time, featuring key opinion leader (KOL) Dr. Mary Kay Koenig fr...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771 entitled Process for the Preparation of...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company’s lead rare pediatric neurodegenerative disease indication, Ataxi...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology.
“A-T...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consu...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2024.
Dirk Thye, M.D., Quince’s Chief...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences:
2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference o...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807)...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
CRTX
LISTED
NASDAQ
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2024.
Dirk Thye, M.D., Quince’s Chief Exec...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
